Cargando…
Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine
Zika virus (ZIKV) infections are spreading silently with limited global surveillance in at least 89 countries and territories. There is a pressing need to develop an effective vaccine suitable for equitable distribution globally. Consequently, we previously developed a proprietary DNA vaccine encodi...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630652/ https://www.ncbi.nlm.nih.gov/pubmed/38028199 http://dx.doi.org/10.1016/j.omtn.2023.102056 |
_version_ | 1785132196732862464 |
---|---|
author | Wijesundara, Danushka K. Yeow, Arthur McMillan, Christopher L.D. Choo, Jovin J.Y. Todorovic, Aleksandra Mekonnen, Zelalem A. Masavuli, Makutiro G. Young, Paul R. Gowans, Eric J. Grubor-Bauk, Branka Muller, David A. |
author_facet | Wijesundara, Danushka K. Yeow, Arthur McMillan, Christopher L.D. Choo, Jovin J.Y. Todorovic, Aleksandra Mekonnen, Zelalem A. Masavuli, Makutiro G. Young, Paul R. Gowans, Eric J. Grubor-Bauk, Branka Muller, David A. |
author_sort | Wijesundara, Danushka K. |
collection | PubMed |
description | Zika virus (ZIKV) infections are spreading silently with limited global surveillance in at least 89 countries and territories. There is a pressing need to develop an effective vaccine suitable for equitable distribution globally. Consequently, we previously developed a proprietary DNA vaccine encoding secreted non-structural protein 1 of ZIKV (pVAX-tpaNS1) to elicit rapid protection in a T cell-dependent manner in mice. In the current study, we evaluated the stability, efficacy, and immunogenicity of delivering this DNA vaccine into the skin using a clinically effective and proprietary high-density microarray patch (HD-MAP). Dry-coating of pVAX-tpaNS1 on the HD-MAP device resulted in no loss of vaccine stability at 40°C storage over the course of 28 days. Vaccination of mice (BALB/c) with the HD-MAP-coated pVAX-tpaNS1 elicited a robust anti-NS1 IgG response in both the cervicovaginal mucosa and systemically and afforded protection against live ZIKV challenge. Furthermore, the vaccination elicited a significantly higher magnitude and broader NS1-specific T helper and cytotoxic T cell response in vivo compared with traditional needle and syringe intradermal vaccination. Overall, the study highlights distinctive immunological advantages coupled with an excellent thermostability profile of using the HD-MAP device to deliver a novel ZIKV DNA vaccine. |
format | Online Article Text |
id | pubmed-10630652 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-106306522023-10-16 Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine Wijesundara, Danushka K. Yeow, Arthur McMillan, Christopher L.D. Choo, Jovin J.Y. Todorovic, Aleksandra Mekonnen, Zelalem A. Masavuli, Makutiro G. Young, Paul R. Gowans, Eric J. Grubor-Bauk, Branka Muller, David A. Mol Ther Nucleic Acids Original Article Zika virus (ZIKV) infections are spreading silently with limited global surveillance in at least 89 countries and territories. There is a pressing need to develop an effective vaccine suitable for equitable distribution globally. Consequently, we previously developed a proprietary DNA vaccine encoding secreted non-structural protein 1 of ZIKV (pVAX-tpaNS1) to elicit rapid protection in a T cell-dependent manner in mice. In the current study, we evaluated the stability, efficacy, and immunogenicity of delivering this DNA vaccine into the skin using a clinically effective and proprietary high-density microarray patch (HD-MAP). Dry-coating of pVAX-tpaNS1 on the HD-MAP device resulted in no loss of vaccine stability at 40°C storage over the course of 28 days. Vaccination of mice (BALB/c) with the HD-MAP-coated pVAX-tpaNS1 elicited a robust anti-NS1 IgG response in both the cervicovaginal mucosa and systemically and afforded protection against live ZIKV challenge. Furthermore, the vaccination elicited a significantly higher magnitude and broader NS1-specific T helper and cytotoxic T cell response in vivo compared with traditional needle and syringe intradermal vaccination. Overall, the study highlights distinctive immunological advantages coupled with an excellent thermostability profile of using the HD-MAP device to deliver a novel ZIKV DNA vaccine. American Society of Gene & Cell Therapy 2023-10-16 /pmc/articles/PMC10630652/ /pubmed/38028199 http://dx.doi.org/10.1016/j.omtn.2023.102056 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Wijesundara, Danushka K. Yeow, Arthur McMillan, Christopher L.D. Choo, Jovin J.Y. Todorovic, Aleksandra Mekonnen, Zelalem A. Masavuli, Makutiro G. Young, Paul R. Gowans, Eric J. Grubor-Bauk, Branka Muller, David A. Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine |
title | Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine |
title_full | Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine |
title_fullStr | Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine |
title_full_unstemmed | Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine |
title_short | Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine |
title_sort | superior efficacy of a skin-applied microprojection device for delivering a novel zika dna vaccine |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630652/ https://www.ncbi.nlm.nih.gov/pubmed/38028199 http://dx.doi.org/10.1016/j.omtn.2023.102056 |
work_keys_str_mv | AT wijesundaradanushkak superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine AT yeowarthur superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine AT mcmillanchristopherld superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine AT choojovinjy superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine AT todorovicaleksandra superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine AT mekonnenzelalema superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine AT masavulimakutirog superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine AT youngpaulr superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine AT gowansericj superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine AT gruborbaukbranka superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine AT mullerdavida superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine |